Form 4: Mural Oncology Executive Sells Shares Under 10b5-1 Trading Plan

Maiken Keson-Brookes, Chief Legal Officer and Secretary of Mural Oncology, sold 2,555 ordinary shares at an average price of $3.27 under a pre-arranged 10b5-1 trading plan.

Summary

• Maiken Keson-Brookes, the Chief Legal Officer and Secretary of Mural Oncology, sold 2,555 ordinary shares of the company.
• The sale occurred on December 23, 2024, at a weighted average price of $3.27 per share.
• The shares were sold under a pre-arranged Rule 10b5-1 trading plan established on September 20, 2024.
• The sale was executed in multiple transactions with prices ranging from $3.24 to $3.33 per share.
• Following the transaction, Ms. Keson-Brookes beneficially owns 41,295 shares, which includes 38,705 unvested restricted stock units.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 trading plans to avoid accusations of trading on inside information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies to manage their personal finances and avoid potential insider trading issues.
• The sale of shares by an executive is a normal occurrence and does not necessarily indicate a negative outlook for the company.
• Similar filings are regularly made by executives at other biotech companies such as Amgen, Gilead, and Regeneron.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but it is unlikely to significantly affect the company's stock price given the pre-arranged nature of the transaction.

Key Dates

Keywords

Mural Oncology, insider trading, Form 4, share sale, 10b5-1 plan, Maiken Keson-Brookes, executive sale, stock transaction